Roblon A/S : Interim report for Q2 2014/15 and for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Roblon A/S : Interim report for Q2 2014/15 and for the half-year 1 November 2014 - 30 April 2015

Interim report for Q2 2014/15 and for the half-year 1 November 2014 - 30 April 2015 Roblon's expectations for 2014/15 unchanged

  • Revenue for the first half-year of 2014/15 amounted to DKK 112.7 million (124.8 million)   
  • Operating profit for the first half-year of 2014/15 (EBIT) amounted to DKK 19.4 million (22.2 million)   
  • EBIT margin of 17.2% for the first half-year of 2014/15 (17.8%)  
  • Profit before tax for the first half-year of 2014/15 amounted to DKK 20.9 million (22.9 million)   
  • Net profit for the first half-year of 2014/15 amounted to DKK 16.0 million (17.3 million)   
  • The sales organisation was strengthened in the first half-year of 2014/15, with further consolidation expected over the course of the financial year.   
  • More investment in developing new products.   
  • The management is not making any changes to its expectations from company announcement No 4 issued on 26 February 2015, which were that revenue and earnings would be in the order of DKK 250-280 million and DKK 40-50 million before tax  respectively.  

Frederikshavn, 18 June 2015 Roblon A/S   

Jørgen Kjær Jacobsen                     Jens-Ole Sørensen Chairman of the Board                     Managing Director 

Interim Report 2014/15 http://hugin.info/2201/R/1924879/692888.pdf

HUG#1924879

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading